Use of the Activated Partial Thromboplastin Time for Heparin Monitoring

American Journal of Clinical Pathology

Volumn 115, Issue 1, 2001, Pages 148-155

  Smythe, Maureen A ^a,b   Koerber, John M ^a,b   Westley, Susan J ^a   Nowak, Sandra N ^b   Begle, Robert L ^a   Balasubramaniam, Mamtha ^a   Mattson, Joan C ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Activated partial thromboplastin time; aPTT; Heparin; Therapeutic range

Indexed keywords

HEPARIN;

AGED; ARTICLE; BLOOD; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DOSE RESPONSE; DRUG MONITORING; FEMALE; HOSPITAL INFORMATION SYSTEM; HUMAN; LABORATORY; MALE; METHODOLOGY; MIDDLE AGED; OSMOLARITY; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HEPARIN; HUMANS; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES;

EID: 0035234252     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/N7RA-D6XN-9EQX-ABJ9     Document Type: Article

References (19)

1. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin, mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest. 1998;114(5 suppl):489S-510S.
2. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798.
3. Koerber JM, Smythe MA, Begle RL, et al. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotheratry. 1999;19:922-931.
4. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels: time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157:2475-2479.
5. Rosborough TK. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol. 1997;108:662-668.
6. Taylor CT, Petros WP, Ortel TL. Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring, Pharmacotherapy. 1999;19:383-387.
7. van den Besselaar AMHP, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples, Thromb Haemost. 1990;63:16-23.
8. Despotis GJ, Hogue CW, Santoro SA, et al. Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor. Crit Care Med. 1995;23:1674-1679.
9. Reiner JS, Coyne KS, Lundergan CF, et al. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn. 1994;32:49-52.
10. Gosselin RC, Owings JT, Pollock ME, et al. Evaluation of a point-of-care coagulation device, the thrombolytic assessment system (TAS), for measuring prothrombin times, activated partial thromboplastin times, and high-dose heparin anticoagulation. Lab Hematol. 1998;4:217-224.
11. Werner M, Gallagher JV, Ballo MS, et al. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions in heparin therapy. Am J Clin Pathol. 1994;102:237-241.
12. Snedcor GW, Cochran WG. Correlation. In: Statistical Methods. 6th ed. Ames, IA: Iowa State University Press; 1980:185-188.
13. SAS Institute Inc. SAS/STAT User's Guide. Version 6. Vol 1. 4th ed. Cary, NC: SAS Institute; 1989:893-996.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
15. National Committee for Clinical Laboratoty Standards. Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline. 3rd ed. H21-A3. Wayne, PA: National Committee for Clinical Laboratory Standards; 1998.
16. O'Neill Al, McAllister C, Corke CF, et al. A comparison of five devices for the bedside monitoring of heparin therapy, Anaesth Intensive Care. 1981;19:592-601.
17. Blumenthal RS, Carter AJ, Resar JR, et al. Comparison of bedside and hospital laboratory coagulation studies during and after coronary intervention. Cathet Cardiovac Diagn. 1995;35:9-17.
18. Gibbs NM, Weightman WM, Thackray NM, et al. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. J Cardiothorac Vasc Anesth. 1998;12:536-541.
19. Reich DL, Yanakakis MJ, Vela-Cantos FP, et al. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery. Anesth Analg. 1993;77:673-679.